JP Morgan Chase’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

JP Morgan Chase’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-193	Closed	-$114	–	7834
2024 Q4	$114	Sell	193 -1	-0.5%	-$1	﹤0.01%	6993
2024 Q3	$153	Buy	194 +41	+27%	+$41	﹤0.01%	6941
2024 Q2	$194	Hold	153	–	–	﹤0.01%	6792
2024 Q1	$213	Buy	153 +135	+750%	+$223	﹤0.01%	6801
2023 Q4	$29	Sell	18 -222	-93%	-$283	﹤0.01%	7288
2023 Q3	$341	Buy	+240	New	+$369	﹤0.01%	6772

JP Morgan Chase's CYTH Position: Q1 2025 in Review

JP Morgan Chase sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 193 shares — an estimated $114 sold.

JP Morgan Chase first reported a position in CYTH in Q3 2023 and held it in 6 quarters. The position peaked at $341 in Q3 2023. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

JP Morgan Chase reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
JP Morgan Chase sold 193 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $114.
JP Morgan Chase first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q3 2023 and held it in 6 quarters.
JP Morgan Chase's Cyclo Therapeutics, Inc. Common Stock position peaked at $341 in Q3 2023.
0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.